SciClone Pharmaceuticals   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Foster City CA United States (2003)

Organization Overview

First Clinical Trial
2003
NCT00004428
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

SciClone Pharmaceuticals

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 4)

Carcinoma, Hepatocellular (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Cystic Fibrosis (Phase 1)

Fibrosis (Phase 1)

Head and Neck Neoplasms (Phase 2)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Hepatitis, Chronic (Phase 4)

Lung Neoplasms (Phase 2)

Mucositis (Phase 2)

Sepsis (Phase 3)

Stomatitis (Phase 2)

Toxemia (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 21
  • # of Trial APIs: 19